Skip to content
Homepage
Author:
Nuvation Bio, Inc.
Posted Date:
July 22, 2026
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Nuvation Bio, Inc.
July 22, 2026
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Nuvation Bio, Inc.
July 20, 2026
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio, Inc.
July 6, 2026
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
Nuvation Bio, Inc.
June 29, 2026
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio, Inc.
June 26, 2026
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Nuvation Bio, Inc.
June 25, 2026
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio, Inc.
May 30, 2026
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio, Inc.
May 30, 2026
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio, Inc.
May 28, 2026
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio, Inc.
May 27, 2026
1
2
3
Next
